Literature DB >> 33278773

Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab.

Jacopo Giuliani1, Francesco Fiorica2, Vito Albanese3, Andrea Bonetti4.   

Abstract

Entities:  

Keywords:  Bevacizumab; Biosimilar; Cost of drugs; Phase III RCT

Mesh：

Substances：

Year:  2020        PMID： 33278773     DOI： 10.1016/j.ejca.2020.11.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  Financial toxicity in patients with lung cancer: a scoping review protocol.

Authors:  Liang Fu; Minling Zhuang; Chengcan Luo; Ruiyun Zhu; Bei Wu; Wenxia Xu; Bo Xu; Ruiyan Xu; Xianghong Ye
Journal:  BMJ Open       Date:  2022-05-24       Impact factor: 3.006

2.  Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US.

Authors:  Ran Jin; Reshma L Mahtani; Neil Accortt; Tatiana Lawrence; Darcie Sandschafer; Arturo Loaiza-Bonilla
Journal:  Ther Adv Med Oncol       Date:  2021-09-01       Impact factor: 8.168

3.  Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.

Authors:  Adam Fundytus; Manju Sengar; Dorothy Lombe; Wilma Hopman; Matthew Jalink; Bishal Gyawali; Dario Trapani; Felipe Roitberg; Elisabeth G E De Vries; Lorenzo Moja; André Ilbawi; Richard Sullivan; Christopher M Booth
Journal:  Lancet Oncol       Date:  2021-09-21       Impact factor: 41.316
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.